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Summary Overexpression of the MDR] product, P-glycoprotein (Pgp), has been shown to be one of the
mechanisms underlying the development of multidrug resistance (MDR). Recently, one mutant p53 has been
shown to stimulate the MDRJ gene promoter in vitro, whereas wild-type p53 repressed this activity. We
measured Pgp and p53 expression by immunoblotting in 34 colorectal tumours, and performed mutation
analyses on the p53-positive tumours to confirm the presence of mutant p53 protein. Tumour DNA indices
(Dls) were also measured using flow cytometry. Pgp was detected in 44% (15/34) of the tumours and in 100%
(13/13) of the normal mucosas (P = 0.0005), with highest levels of expression seen in normal mucosa,
suggesting that initial drug resistance in colorectal tumours is not caused by Pgp. Highly DNA aneuploid
tumours demonstrated the lowest levels of Pgp expression relative to moderately aneuploid and diploid
colorectal tumours. p53 protein was detected in 53% (18/34) of the tumours, and 12 of 14 p53-positive
tumours had p53 gene mutations. p53-negative tumours had approximately twice the level of Pgp expression
of p53-positive tumours. Pgp expression was not associated with either p53 expression (P = 0.73) or incidence
of p53 gene mutation (P = 0.70), suggesting that mutant p53 does not induce Pgp overexpression in colorectal
carcinomas.
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A majority of colorectal carcinomas and other solid tumours
are resistant to cytostatic drugs, which is a significant prob-
lem in their treatment (de Vries and Pinedo, 1991). The cause
of such resistance may be determined not only by specific
cellular mechanisms such as the multidrug resistance (MDR)
phenotype associated with overexpression of the MDRJ gene,
but also by characteristics of the tumour population, such as
the proportion of quiescent cells and adequacy of blood
supply (Judson, 1992).
The MDR] gene product, a 170 kDa protein known as
P-glycoprotein (Pgp), appears to be a bifunctional transmem-
brane protein that functions both as an energy-dependent
drug efflux pump of broad specificity (e.g. for anthracyclines
and other natural hydrophobic compounds) and as a chloride
channel (Gill et al., 1992). Several studies have shown that
MDR can be conferred upon drug-sensitive cells by transfer
of genes encoding Pgp (Gros et al., 1986; Ueda et al., 1987).
MDR] RNA and Pgp are found at substantial levels in
normal colon, small intestine, kidney, liver and adrenal gland
(Fojo et al., 1987), suggesting a normal transporter role for
Pgp in these tissues. Pgp has also been found in untreated
human cancers derived from normal tissues that express Pgp,
such as carcinomas of the colon, liver, kidney, pancreas and
adrenal gland (Goldstein et al., 1989). However, it has also
been shown that expression of low constitutive levels of
MDR] mRNA/Pgp may not necessarily result in the func-
tional expression of the MDR phenotype (Hamada et al.,
1987; Chambers et al., 1990; Kramer et al., 1993).
Chin et al. (1992) have recently shown that one mutant
human p53 protein has a specific stimulatory effect upon the
MDR] gene promoter in 3T3 cells and that wild-type p53
exerts specific repression. Expression of p53 protein in col-
orectal carcinomas is associated with a high degree of tumour
DNA aneuploidy (Carder et al., 1993; De Angelis et al.,
1993) and a high incidence of p53 gene mutation (De Angelis
et al., 1993). It could be speculated that highly aneuploid
tumours with mutant p53 express excess Pgp as a result of
the stimulatory effect of p53 on the MDR] gene. In this
study we have measured Pgp expression and p53 expression
in 34 colorectal tumours in order to determine whether Pgp
expression is likely to confer initial drug resistance and
whether mutant p53 stimulates Pgp expression in vivo.
Materials and methods
Clinical material
Thirty-four surgically removed and previously untreated col-
orectal carcinomas and 13 normal colonic mucosas were
collected and studied. All tumours were classified according
to Dukes' stage (Dukes, 1932) and histological grade (Jass et
al., 1986) (Table I, includes tumour site). Normal mucosa
samples were selected from macroscopically normal areas of
surgical specimens. Fresh tumour (T) and normal mucosa
(N) samples were frozen without buffer at - 80C
immediately after surgery. During tissue sectioning and
preparation procedures for DNA ploidy analysis and
immunoblotting, the tumours and normal mucosas were kept
on dry ice until used.
DNA indices (DIs) were determined for the tumour set
using laser flow cytometry as described previously (De
Angelis et al., 1993), and are presented in Table I. The DI
characterises a tumour as either DNA aneuploid (DI > 1.00)
or diploid (DI = 1.00) (Hiddemann et al., 1984; Dressler and
Bartow, 1989). Highly DNA aneuploid tumours were defined
as those with a DI > 1.30, and moderately DNA aneuploid
(hyperdiploid) tumours as those with a DI > 1.00 and
<1.30. The DI has been used as a prognostic parameter
(with modest impact, Bauer et al., 1993) in addition to
Dukes' stage and histological grade classifications for the
prediction of prognosis of patients with colorectal
tumours.
Immunoblotting
Slices (approximately 0.5-1.0 mm thick) of tumour and nor-
mal mucosa were cut with scalpels and boiled for 3-4 min in
sodium dodecyl sulphate (SDS) sample buffer (Laemmli,
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Table I Tumour site, Dukes' stage, histological grade and DNA
index (DI) for 34 colorectal tumours
Tumour
Tumour site
90- 1 Left colon
90-4 Right colon
90-7 Right colon
90-8 Rectum
90-9 Left colon
90-10 Right colon
90- 19 Rectum
90-20 Right colon
92-1 Left colon
92-2 Left colon
92-4 Right colon
92-5 Left colon
92-6 Right colon
92-8 Left colon
92-9 Right colon
92-10 Right colon
94- 1 Left colon
94-3 Rectum
94-6 Left colon
94-7 Rectum
94-8 Left colon
94-9 Left colon
94- 10 Rectum
94- 13 Rectum
94-14 Rectum
94- 15 Rectum
94-16 Left colon
94- 17 Rectum
94-18 Left colon
94-19 Right colon
94-21 Right colon
94-23 Left colon
94-24 Rectum
94-25 Rectum
PD, poorly differentiated;
highly differentiated.
Dukes
stage
D
C
D
C
B
B
B
B
C
D
B
B
D
D
B
B
B
B
D
A
C
B
D
B
B
C
C
B
C
D
D
B
D
B
MD,
Histologi
grade
PD
MD
PD
MD
MD
MD
MD
MD
MD
MD
MD
MD
PD
HD
MD
MD
MD
MD
PD
MD
MD
MD
MD
MD
MD
MD
PD
MD
MD
PD
MD
MD
MD
MD
moderately
ical DNA index
(DI)
1.21
1.00
.1.10
1.00
1.22
1.00
1.77
1.26
1.70
1.37
1.00
1.49
1.31
1.60
1.15
1.00
1.56
1.00
1.71
1.76
1.94
1.78
1.97
1.59
1.00
1.58
1.39
1.00
1.69
1.00
1.74
1.20
1.70
1.00
differentiated; HD,
265-301 of exon 8. Twenty tumours were also analysed for
mutations in codon region 189-215 of exon 6. The optimal
conditions for PCR and CDGE have been described
elsewhere (Borresen et al., 1991; Smith-Sorensen et al.,
1993).
DNA sequencing
Tumour samples shown to be mutated by CDGE were sub-
mitted to direct sequencing in order to determine exactly
which codon was affected. A new PCR product was made
using primers outside the ones used for CDGE. The PCR
products were sequenced directly with standard dideoxy-
sequencing reactions using Dynabeads M280-streptavidin
(Dynal AS, Oslo, Norway) as solid support (Hultman et al.,
1989). It has previously been shown that CDGE is a more
sensitive method of detecting mutants than this type of
sequencing (Borresen et al., 1991). Therefore not all mutants
found by CDGE were confirmed by sequencing.
Statistical analysis
Fisher's two-tailed 2 x 2 contingency test was used to check
for significance of correlations (P-values) between any two
parameters. P-values <0.05 were considered to denote a
statistically significant difference.
Results
Pgp was detected in 44% (15/34) of the tumours and in
100% (13/13) of the normal mucosas examined (Figure 1;
Table II) (P = 0.0005), with higher levels of expression seen
in normal mucosa generally (mean expression 0.260 ± 0.22)
as assessed by densitometry, in contrast to a mean expression
of0.061 ± 0.12 for all of the tumours. Table III demonstrates
the lower levels of Pgp expression in a subset of the tumour
group compared with the levels seen in the corresponding
normal mucosas; it was observed in two cases (92-5 and 92-9)
1970) containing protease inhibitors. Representative slices
were also cut from the same areas of the tumours as used for
immunoblotting, processed for routine histology, and
examined by one of us (OPFC) in order to estimate the
percentages of tumour and normal mucosal cells in each
section. The mean percentage of tumour cells for all sections
examined (n = 31) was 90.4% ± 12.6%.
The proteins were first separated by electrophoresis in
8.0% SDS-polyacrylamide gels (Laemmli, 1970). Immunob-
lotting was done as described previously (De Angelis et al.,
1993) using the anti-Pgp monoclonal antibody C219 (Cen-
tocor, PA, USA), the anti-p53 monoclonal antibodies PAb
1801 and PAb 421, and the anti-p83 monoclonal antibody
34C1 (courtesy ofT Stokke). The amount ofp83 (nucleoplas-
mic protein expressed at equivalent levels in proliferating and
non-proliferating cells; T Stokke and S Funderud, unpub-
lished) was determined on the same blots in order to control
for gel loading, cell concentration and protein degradation. A
biotin-streptavidin alkaline phosphatase staining procedure
was used to detect the primary antibodies (Amersham, UK).
The amounts of the different proteins were evaluated by
densitometry using ImageQuant densitometry software
(Molecular Dynamics, USA) to analyse stored gel images
generated with an Agfa photo scanner (Agfa, Germany).
Levels of protein expression are reported relative to p83
expression.
Mutation analysis within thep53 gene
DNA from 28 colorectal tumour samples was subjected to
mutation analysis using polymerase chain reaction (PCR)
followed by constant denaturant gel electrophoresis (CDGE).
We screened for mutations in the conserved domains corres-
ponding to the following codons: codons 128-153 and
155-185 of exon 5, codons 237-253 of exon 7 and codons
-Control - -. Pgp/p83/p53
-Pgp
-p83
- p53
co CN N N0 Cc4
N N N N N N N CD CD o) m oz a) aw eo a) 1) a) a)
Figure 1 Immunoblot of colorectal tumours 92-1, 92-2, 92-4 to
92-6, and corresponding normal mucosas 92-iN, 92-2N, 92-4N to
92-6N, stained for Pgp, p83 and p53. The blot to the left is the
control blot (without primary antibodies) for non-specific stain-
ing. The amounts of these proteins were quantified by den-
sitometry and the results presented as fractional values relative to
p83 (Tables II and III). Normal mucosa 92-SN expressed low
levels of Pgp as demonstrated by the weakly stained Pgp band.
The strong p83 bands for both the tumour and normal mucosal
samples indicate lack of protein degradation and that relatively
equal amounts of protein were loaded per lane.P-glycoprotein expression in colorectal tumours
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that the level of Pgp expression in the tumours was higher
than in the corresponding normal mucosas.
There was significant association neither between Pgp exp-
ression and Dukes' stage (A plus B vs C plus D; P = 0.51)
nor between Pgp expression and tumour site in the colon
(P= 1.00, right colon vs left colon/rectum). Additionally,
there was not a significant association between Pgp expres-
sion and histological grade (P = 1.00, poorly differentiated vs
moderately and highly differentiated tumours).
Fifty per cent (12/24) of the aneuploid tumours were
positive for Pgp, compared with 40% (4/10) of the diploid
tumours (P = 0.71). The densitometry results demonstrated a
trend which showed that the highly aneuploid tumours exp-
ressed the lowest amounts of Pgp (mean = 0.034 ± 0.08), the
moderately aneuploid tumours more than double that seen in
the highly aneuploid tumours (mean = 0.086 ± 0.09), the dip-
loid tumours approximately the same amounts as those seen
in the moderately aneuploid tumours (mean = 0.078 ± 0.19)
and the normal mucosas the highest amounts of Pgp
(mean = 0.260 ± 0.22). However, this trend was not
significant since the standard deviations for each sample
group were high and overlapped with the other groups, and
because each of the sample groups tended to be small in
size.
p53 was detected in 53% (18/34) of the tumours (Figure 1;
Table II), whereas none of the normal mucosas expressed
p53. Twelve of 14 p53-positive tumours examined for muta-
tions had p53 gene mutations.
Pgp expression was significantly associated neither with
p53 expression (P = 0.73) nor with incidence of p53 gene
mutations (P = 0.70). The level of Pgp expression in the
p53-positive tumours was determined to be 0.043 ± 0.087,
approximately half the level of expression seen for the p53-
negative tumours (0.081 ± 0.156, although this difference was
not significant because of the high and overlapping standard
deviations for each group.
Discussion
Pgp was expressed in 44% of the colorectal tumours and in
all of the normal mucosas examined in this study, with the
highest levels of expression seen in normal mucosa. The
positive tumours generally expressed less Pgp than normal
mucosa. Our results are in agreement with those of a
previous study (Fujii et al., 1993), which demonstrated that
44% of colon carcinomas were positive for Pgp by
immunofluorescence analyses using both flow cytometry and
immunohistochemistry in sections, as well as with previous
studies demonstrating Pgp expression generally in normal
colonic mucosa (Fojo et al., 1987) and colonic tumours
(Goldstein et al., 1989). Peters et al. (1992) found positive
Pgp expression in all but one tumour; the tumours had
significantly higher levels of Pgp than the normal mucosas.
Table III Pgp is not expressed in many tumours relative to the
corresponding normal mucosas
Fraction Pgp Fraction Pgp
expressed in expressed in
Tumour normal mucosa tumour
90-1 0.576 0.124
90-7 0.074 0.0
90-8 0.059 0.037
90-10 0.733 0.0
92-1 0.269 0.0
92-2 0.207 0.0
92-4 0.298 0.128
92-5 0.091 0.324
92-6 0.344 0.0
92-8 0.131 0.112
92-9 0.076 0.211
Mean ± s.d. 0.260 ± 0.22 0.085 ± 0.11
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Table II Pgp and p53 status for 34 colorectal tumours
Fraction Pgp Pgp Fraction pS3 p53 pS3 Gene mutations
Tumour expressed status expressed status Exon codon Mutation Amino acid
90-1 0.124 + 0.0 -
90-4 0.610 + + 0.0 -
90-7 0.0 - 0.0 - No mutation revealed
90-8 0.037 + 0.0 - No mutation revealed
90-9 0.013 + 0.0 - No mutation revealed
90-10 0.0 - 0.0 - No mutation revealed
90-19 0.191 + 0.171 +
90-20 0.025 + 0.0 - No mutation revealed
92-1 0.0 - 0.232 + Exon 5: codon 175 CGC to CAC Arg to His
92-2 0.0 - 0.724 + + Exon 8: codon 275 TGT to TTT Cys to Phe
92-4 0.128 + 0.0 - No mutation revealed
92-5 0.324 + + 0.860 + + Exon 8: unspecified codon
92-6 0.0 - 0.457 + + Exon 8: codon 282 CGG to TGG Arg to Trp
92-8 0.112 + 0.910 ++ Exon 8: codon 273 CGT to CAT Arg to His
92-9 0.211 + + 0.0 - No mutation revealed
92-10 0.0 - 0.029 -
94-1 0.0 - 0.0 - No mutation revealed
94-3 0.0 - 0.0 - No mutation revealed
94-6 0.012 + 0.162 + Exon 5: unspecified codon
94-7 0.0 - 0.206 +
94-8 0.056 + 0.127 + Exon 7: codon 245 GGC to AGC Gly to Ser
94-9 0.015 + 0.216 + Exon 5: unspecified codon
94-10 0.062 + 0.240 +
94-13 0.0 - 0.270 + Exon 5: codon 130 CTC to CAC Leu to His
94-14 0.0 - 0.113 + Exon 5: codon 176 TGC to TAC Cys to Tyr
94-15 0.0 - 0.0 - Exon 6: codon 196 CGA to TGA Arg to STOP
94-16 0.0 - 0.042 +
94-17 0.0 - 0.062 + No mutation revealed
94-18 0.0 - 0.116 + Exon 5: unspecified codon
94-19 0.0 - 0.195 + No mutation revealed
94-21 0.0 - 0.269 + + Exon 6: unspecified codon
94-23 0.142 + + 0.0 - No mutation revealed
94-24 0.0 - 0.0 - Exon 5: unspecified codon
94-25 0.0 - 0.0 - No mutation revealed
In the columns 'Pgp status' and 'p53 status', the amounts of each protein were visually evaluated from the immunoblots and described as
absent (-), present in low amounts (+) and present in high amounts (+ +).P-glyoprotein expression incolorectal tumours
P-glycoprotin P De Angelis etal
310
This discrepancy could be explained by their lack of gel
loading/concentration standards when quantifying Pgp exp-
ression (p83 in our study) and different methods of isolation
of cells from tumour and mucosal samples.
More than half of the colorectal tumours examined in this
study were negative for Pgp expression, possibly reflecting
their clonal origin from a cell which did not originally exp-
ress Pgp (Noonan et al., 1990). This Pgp-negative cell might
be a crypt epithelial cell, since these have been shown to be
negative for Pgp expression, whereas the surface epithelial
cells lining the lumen (apical brush border cells) are Pgp-
positive (Cordon-Cardo et al., 1990). This reflects a
differentiation-dependent pattern of expression as normal
mucosal cells move up the crypt toward the surface. We
estimated the percentage of normal mucosal cells in the
tumour sections which might influence the number of Pgp-
positive tumours scored. We are confident that the immunob-
lotting results reflect the biological characteristics of tumour
cells, since very few non-tumour epithelial cells were seen in
the sections examined (<10%) from the same areas of the
tumours used for immunoblotting. Several tumours in our
study which contained some normal cells were not scored as
positive, thus contamination is not a significant problem in
this study. It may mean, however, that heterogeneous
tumours with a low number of Pgp-positive cells may be
scored as Pgp-negative. Heterogeneity of Pgp staining and
tumour sampling are other factors which may influence the
number of positive tumours scored. However, these factors
do not influence our main conclusion, which is that colorec-
tal tumours either do not express Pgp at all (lack of
differentiated phenotype) or do so to a much lesser extent
than normal mucosa.
There was no correlation of Pgp expression with Dukes'
stage, histological grade, or tumour site, confirming the
results of Pirker et al. (1993). We also found no significant
correlation between Pgp expression and DNA aneuploidy,
consistent with the results of Sinicrope et al. (1994). How-
ever, these results are not in agreement with those of Danova
et al. (1992), who demonstrated a correlation between DNA
aneuploidy and higher levels of Pgp expression relative to
diploid tumours and normal tissue.
Chin et al. (1992) found that one mutant human p53
protein (point mutation at codon 175, Arg to His substitu-
tion) had a specific stimulatory effect upon the MDR] gene
promoter in 3T3 cells, suggesting that colon tumours which
express mutant p53 should overexpress Pgp (relative to the
levels of Pgp expressed in normal mucosa). However, we
found no association between mutant p53 and Pgp expres-
sion. Where there was Pgp expression in the p53-positive
tumours, it was still lower than that seen in normal mucosa.
Additionally, tumour 92-1 in our tumour set expressed the
particular codon 175 mutant p53 as studied by Chin et al.
(1992), but did not express Pgp. This independence of Pgp
and mutant p53 expression is supported by recent studies of
B-cell chronic lymphocytic leukaemia (El Rouby et al., 1993),
acute myelogenous leukaemia (Zhao et al., 1992) and
myelodysplastic syndromes (Preudhomme et al., 1993), which
demonstrated that MDRJ gene overexpression is independent
of p53 gene mutations/mutant p53 protein.
It was not possible in this study directly to correlate Pgp
expression in colon carcinomas with response to cytostatics
and overall survival, since only one of the patients received
chemotherapy for his tumour. However, the lack of Pgp
expression in many colon tumours suggests that resistance
mechanisms other than MDR are responsible for the initial
resistance to cytostatic drugs often seen in colon tumours.
Non-MDR' mechanisms which have been shown to be
involved in mediating resistance to cytostatic drugs (other
than anthracyclines) in colon tumours are the activity of
glutathione S-transferase (Waxman, 1990; Clapper et al.,
1991; De Waziers et al., 1991; Moorghen et al., 1991; Peters
et al., 1992) and the alteration of DNA-associated
topoisomerase II which is involved in post-replication repair
(Redmond et al., 1991).
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